Yr Athro Richard Adams

(e/fe)

B.Med.Sci, BM BS, MRCP, FRCR, MD

2026

• Gilbert, A. et al., 2026. Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials. Radiotherapy and Oncology 223 111706. (10.1016/j.radonc.2026.111706)
• DharmishaChauhan, D. et al., 2026. UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology 92 (9), pp.2986-3001. (10.1002/bcp.70659)
• Nada Benhima, N. B. et al., 2026. Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy. European Journal of Cancer 245 116911. (10.1016/j.ejca.2026.116911)
• Anwer, S. et al., 2026. Visualization of multi-indication randomized control trial evidence to support decision making in oncology: a case study on bevacizumab. Medical Decision Making 46 (6), pp.716-729. (10.1177/0272989x261430333)
• Sebag-Montefiore, D. et al., 2026. Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial. The Lancet Oncology 27 (8), pp.1004-1019. (10.1016/s1470-2045(26)00132-4)
• Samaille, T. et al., 2026. Prognostic value of liver metastases and KRAS mutations in patients with metastatic colorectal cancer: A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC database. Clinical Colorectal Cancer (10.1016/j.clcc.2026.05.007)
• Plumpton, C. O. et al., 2026. Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales. British Journal of Clinical Pharmacology (10.1002/bcp.70617)
• Jones, S. E. et al. 2026. PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. Pleura and Peritoneum (10.1515/pp-2025-0023)
• Theophanous, S. et al., 2026. An international multi-centre study to develop and validate federated learning-based prognostic models for anal cancer. Nature Communications 17 3956. (10.1038/s41467-026-70297-3)
• Hawkins, M. A. et al., 2026. Early outcomes of the PLATO ACT5 randomised trial: Personalizing anal cancer radiotherapy dose [Abstract]. Journal of Clinical Oncology 44 (2 supp)(10.1200/jco.2026.44.2_suppl.1)

2025

• Audisio, A. et al., 2025. Total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncology 11 (9), pp.1045-1054. (10.1001/jamaoncol.2025.2026)
• Andreyev, J. et al., 2025. British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer. Gut 74 , pp.1040-1067. (10.1136/gutjnl-2024-333812)
• Jin, Z. et al., 2025. Response to biologics in patients with early-onset treatment-naïve metastatic colorectal cancer—an aide et recherche en cancérologie digestive database analysis. JCO Oncology Advances 2 (1) e2400080. (10.1200/OA-24-00080)
• Bachet, J. et al., 2025. Characteristics of patients and prognostic factors across treatment lines in metastatic colorectal cancer: an analysis from the Aide et Recherche en Cancérologie Digestive database. Journal of Clinical Oncology 43 (18), pp.2094-2106. (10.1200/jco-24-01968)
• Baddeley, E. et al. 2025. Wellbeing and coping: Key aspects of unmet need of people living with glioma. Neuro Oncology Practice 12 (3), pp.413-425. npae127. (10.1093/nop/npae127)
• Gilbert, A. et al., 2025. Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial. The Lancet Oncology 26 (6), pp.707-718. (10.1016/S1470-2045(25)00213-X)
• Bregni, G. et al., 2025. EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases. Cancer Treatment Reviews 136 102926. (10.1016/j.ctrv.2025.102926)
• Macnair, A. et al., 2025. Neoadjuvant treatment of rectal cancer: A repeat UK-wide survey after implementation of national intensity modulated radiotherapy guidance. Clinical Oncology 41 103835. (10.1016/j.clon.2025.103835)
• Aroldi, F. et al., 2025. A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC). BMC Cancer 25 (1) 658. (10.1186/s12885-025-14068-1)
• Wasan, H. and Adams, R. 2025. Colorectal cancer. In: Price, P. and Sikora, K. eds. Treatment of Cancer. Taylor & Francis Group. , pp.249-270. (10.1201/9781003433064-15)
• Gallagher, P. et al., 2025. A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.. BJC Reports 3 (1) 17. (10.1038/s44276-025-00133-6)
• Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)

2024

• Samuel, R. et al., 2024. International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set. EClinicalMedicine 78 102939. (10.1016/j.eclinm.2024.102939)
• Adams, R. et al. 2024. The impact of national radiotherapy guidelines: the UK anal cancer story. Clinical Oncology 36 , pp.593-595. (10.1016/j.clon.2024.06.048)
• Ajakaiye, A. et al., 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting Dublin, Ireland 16-18 October 2024. Vol. 34.BMJ Publishing Group. , pp.A350-A351. (10.1136/ijgc-2024-IGCS.611)
• Cohen, R. et al., 2024. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. European Journal of Cancer 207 114160. (10.1016/j.ejca.2024.114160)
• Murphy, A. D. et al., 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34 , pp.1034-1040. (10.1136/ijgc-2024-005455)
• Karapetis, C. S. et al., 2024. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cancer 130 , pp.1269–1278. (10.1038/s41416-024-02604-y)
• Cohen, R. et al., 2024. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. European Journal of Cancer 199 113537. (10.1016/j.ejca.2024.113537)
• Coyle, V. et al., 2024. Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial. Clinical Microbiology and Infection 30 (1), pp.92-99. (10.1016/j.cmi.2023.07.021)
• Elwood, P. et al. 2024. Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against. British Journal of Cancer 130 , pp.3-8. (10.1038/s41416-023-02506-5)

2023

• Retzer, A. et al., 2023. Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study. Neuro-Oncology Advances 5 (1) vdad096. (10.1093/noajnl/vdad096)
• Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress Istanbul, Turkey 28 September - 01 October 2023. BMJ Publishing Group(10.1136/ijgc-2023-ESGO.690)
• Richman, S. D. et al., 2023. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology 76 (8), pp.548-554. (10.1136/jclinpath-2022-208233)
• Ou, F. et al., 2023. Evaluation of intratumoral response heterogeneity in metastatic colorectal cancer and Its impact on patient overall survival: findings from 10,551 patients in the ARCAD database. Cancers 15 (16) 4117. (10.3390/cancers15164117)
• Mukherjee, S. et al., 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61 102059. (10.1016/j.eclinm.2023.102059)
• Spary, L. K. et al. 2023. Clinical analysis of the colorectal cohort within the Wales cancer biobank: a study of outcomes and genetic screening. Journal of Cancer Therapy 14 (07), pp.317-344. (10.4236/jct.2023.147027)
• Margalit, O. et al., 2023. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.. European Journal of Cancer 178 , pp.162-170. (10.1016/j.ejca.2022.10.022)

2022

• Brown, L. C. et al., 2022. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. Efficacy and Mechanism Evaluation 9 9. (10.3310/HTNB6908)
• Franko, J. et al., 2022. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. European Journal of Cancer 174 , pp.142-152. (10.1016/j.ejca.2022.07.021)
• Retzer, A. et al., 2022. Core outcomes in brain tumour trials – the COBra study review of glioma trial registration data [Abstract]. Neuro-Oncology 24 (10.1093/neuonc/noac200.019)
• Henderson, R. H. et al., 2022. Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy 33 100342. (10.1016/j.jcpo.2022.100342)
• Retzer, A. et al., 2022. Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study. BMJ Open 12 057712. (10.1136/bmjopen-2021-057712)
• Tazi, Y. et al., 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13 (1) 4622. (10.1038/s41467-022-32103-8)
• Brown, S. R. et al., 2022. A road map for designing phase I clinical trials of radiotherapy-novel agent combinations. Clinical Cancer Research 28 (17), pp.3639-3651. (10.1158/1078-0432.CCR-21-4087)
• Margalit, O. et al., 2022. P-106 Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. Annals of Oncology 33 (S4), pp.S287-S287. (10.1016/j.annonc.2022.04.196)
• Speirs, V. et al., 2022. A biobank perspective on use of tissue samples donated by trial participants. The Lancet Oncology 23 (5) e205. (10.1016/S1470-2045(22)00186-3)
• McCleary, N. J. et al., 2022. Metastatic colorectal cancer outcomes by age among ARCAD first- and second-line Clinical trials. JNCI Cancer Spectrum 6 (2) pkac014. (10.1093/jncics/pkac014)
• Adams, R. et al. 2022. Reply to A. Kurreck et al and M.S. Copur et al. Journal of Clinical Oncology 40 (11), pp.1263-1264. (10.1200/JCO.21.02806)
• Brown, L. C. et al., 2022. Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials 19 (2), pp.146-157. (10.1177/17407745211069879)
• Papamichael, D. et al., 2022. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. European Journal of Cancer 163 , pp.1-15. (10.1016/j.ejca.2021.12.007)
• Baddeley, E. et al. 2022. Evaluation of patient and public involvement in the development of a patient reported outcome set in brain tumour trials (COBra Study). Presented at: National PROMs Annual Research Conference Online 14-15 June 2022.
• Goldberg, R. M. et al., 2022. Clinical trial endpoints in metastatic cancer: using individual participant data to inform future trials methodology. Journal of the National Cancer Institute 114 (6), pp.819-828. (10.1093/jnci/djab218)

2021

• Yin, J. et al., 2021. Prognostic and predictive impact of primary tumor sidedness for previously untreated advanced colorectal cancer. Journal of the National Cancer Institute 113 (12), pp.1705-1713. djab112. (10.1093/jnci/djab112)
• Clifford, R. E. et al., 2021. Rectal cancer management during the COVID-19 pandemic (ReCaP): multicentre prospective observational study. British Journal of Surgery 108 (11), pp.1270-1273. znab129. (10.1093/bjs/znab129)
• Adams, R. A. et al. 2021. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology 39 (33), pp.3693-3704. (10.1200/JCO.21.01436)
• Seligmann, J. F. et al., 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39 (33), pp.3705-3715. (10.1200/JCO.21.01435)
• Cohen, R. et al., 2021. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. JNCI: Journal of the National Cancer Institute 113 (10), pp.1386–1395-1395. (10.1093/jnci/djab042)
• ten Hoorn, S. et al., 2021. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer 125 , pp.1080-1088. (10.1038/s41416-021-01477-9)
• Adams, R. et al. 2021. Treatment breaks in first line treatment of advanced colorectal cancer: an individual patient data meta-analysis. Cancer Treatment Reviews 99 102226. (10.1016/j.ctrv.2021.102226)
• Henderson, R. H. et al., 2021. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. The Lancet Gastroenterology & Hepatology 6 (9), pp.709-722. (10.1016/S2468-1253(21)00147-3)
• Hanna, C. R. et al., 2021. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology 16 (1) 163. (10.1186/s13014-021-01888-1)
• Hanna, C. R. et al., 2021. Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology 4 (2), pp.86-104. (10.36401/JIPO-20-31)
• RECOVERY Collaborative Group, , Adams, R. and Forton, J. 2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet 397 (10289), pp.2049-2059. (10.1016/s0140-6736(21)00897-7)
• Hanna, C. et al., 2021. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology 33 (4), pp.214-223. (10.1016/j.clon.2020.12.011)
• Bach, S. P. et al., 2021. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterology and Hepatology 6 (2), pp.92-105. (10.1016/S2468-1253(20)30333-2)
• Horby, P. et al., 2021. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384 (8), pp.693-704. (10.1056/NEJMoa2021436)
• Yin, J. et al., 2021. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology 13 , pp.1-11. (10.1177/17588359211020547)
• Jayson, G. et al., 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference Virtual 2021.

2020

• Horby, P. et al., 2020. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine 383 (21), pp.2030-2040. (10.1056/NEJMoa2022926)
• Glynne-Jones, R. et al., 2020. Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. Annals of Oncology 31 (11), pp.1587-1588. (10.1016/j.annonc.2020.08.2097)
• Germetaki, T. et al., 2020. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncology 16 (28), pp.2177-2189. (10.2217/fon-2020-0523)
• Glynne-Jones, R. et al., 2020. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Annals of Oncology 31 (10), pp.1376-1385. (10.1016/j.annonc.2020.06.012)
• Barber, P. R. et al., 2020. HER2-HER3 heterodimer quantification by FRET-FILM and patient subclass analysis of the COIN colorectal trial. JNCI: Journal of the National Cancer Institute 112 (9), pp.944-954. (10.1093/jnci/djz231)
• Karapetis, C. S. et al., 2020. 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database. Annals of Oncology 31 (S4) S426. (10.1016/j.annonc.2020.08.545)
• Papamichael, D. et al., 2020. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology 31 S425. (10.1016/j.annonc.2020.08.543)
• Rao, S. et al., 2020. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil cersus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology 38 (22), pp.2510-2518. (10.1200/JCO.19.03266)
• O'Cathail, S. M. et al., 2020. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology 15 151. (10.1186/s13014-020-01593-5)
• Forde, C. et al., 2020. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials 21 431. (10.1186/s13063-020-04241-1)
• Gilbert, A. et al., 2020. UK national cohort of anal cancer treated with intensity-modulated radiotherapy: one-year oncological and patient-reported outcomes. European Journal of Cancer 128 , pp.7-16. (10.1016/j.ejca.2019.12.022)
• Chalmers, A. et al., 2020. CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology 32 (1), pp.9-12. (10.1016/j.clon.2019.09.043)

2019

• Joharatnam-Hogan, N. et al., 2019. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology 4 (11), pp.854-862. (10.1016/S2468-1253(19)30289-4)
• Gilbert, A. et al., 2019. 535P - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5). Annals of Oncology 30 (S5), pp.v203-v204. (10.1093/annonc/mdz246.013)
• Vallance, A. et al., 2019. Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. EJSO - European Journal of Surgical Oncology 45 (9), pp.1467-1574. (10.1016/j.ejso.2019.04.005)
• Renehan, A. et al., 2019. Early stage anal margin cancer: towards evidence‐based management. Colorectal Disease 21 (4), pp.387-391. (10.1111/codi.14571)

2018

• Fish, R. et al., 2018. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterology and Hepatology 3 (12), pp.865-873. (10.1016/S2468-1253(18)30264-4)
• West, H. et al. 2018. Role for nucleotide excision repair gene variants in oxaliplatin-induced peripheral neuropathy. JCO Precision Oncology 2 , pp.1-18. (10.1200/PO.18.00090)
• Salem, M. E. et al., 2018. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer 103 , pp.205-213. (10.1016/j.ejca.2018.08.020)
• Cross, W. et al., 2018. The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution 2 (10), pp.1661-1672. (10.1038/s41559-018-0642-z)
• Elwood, P. et al. 2018. Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. PLoS ONE 13 (9), pp.e0203957. (10.1371/journal.pone.0203957)
• Madi, A. et al., 2018. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Presented at: 43rd ESMO Congress 2018 Munich, Germany 19-23 October 2018. Vol. 29.Vol. Supple. Oxford University Press. , pp.VIII22. (10.1093/annonc/mdy269.072)
• Rao, S. et al., 2018. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Presented at: 43rd ESMO Congress 2018 Munich, Germany 19-23 October 2018. Vol. 29.Vol. Supple. Oxford University Press. , pp.VIII715-VIII716. (10.1093/annonc/mdy424.022)
• Goey, K. K. et al., 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer 100 , pp.35-45. (10.1016/j.ejca.2018.05.010)
• Gollins, S. et al. 2018. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer (10.1038/s41416-018-0209-4)
• Jones, C. M. et al., 2018. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort. International Journal of Radiation Oncology - Biology - Physics 101 (5), pp.1202-1211. (10.1016/j.ijrobp.2018.04.033)
• Sjoquist, K. M. et al., 2018. Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project. JNCI: Journal of the National Cancer Institute 110 (6), pp.638-648. (10.1093/jnci/djx253)
• Rose, G. et al., 2018. The cardiopulmonary exercise test grey zone; optimising fitness stratification by application of critical difference. British Journal of Anaesthesia 120 (6), pp.1187-1194. (10.1016/j.bja.2018.02.062)
• Bhoday, J. et al., 2018. Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. Presented at: Future Horizons International Experts Meeting in Colorectal Cancer 2015 London, England 25 June 2015. Published in: Wale, A. and Brown, G. eds. Vol. 20.Vol. S`. Wiley. , pp.97-99. (10.1111/codi.14088)
• Alderdice, M. et al., 2018. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology 245 (1), pp.19-28. (10.1002/path.5051)
• Adams, R. et al. 2018. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2?3 randomised trial. Lancet Gastroenterology and Hepatology 3 (3), pp.162-171. (10.1016/S2468-1253(17)30394-1)
• Lawler, M. et al., 2018. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut 67 (1), pp.179-193. (10.1136/gutjnl-2017-315333)
• Elwood, P. et al. 2018. Healthy living and cancer: evidence from UK Biobank. ecancermedicalscience 12 792. (10.3332/ecancer.2018.792)
• Madi, A. et al. 2018. Pharmacogenetic analyses of 2,183 patients with advanced colorectal cancer; Potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.. European Journal of Cancer 102 , pp.31-39. (10.1016/j.ejca.2018.07.009)

2017

• Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3 (10) e172579. (10.1001/jamaoncol.2017.2579)
• Wasan, H. S. et al., 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology 18 (9), pp.1159-1171. (10.1016/S1470-2045(17)30457-6)
• Battersby, N. J. et al., 2017. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials 18 394. (10.1186/s13063-017-2085-2)
• Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
• Geh, I. et al., 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management ofcancer of the Colon, rectum and anus (2017) - anal cancer. Colorectal Disease 19 (S1), pp.82-97. (10.1111/codi.13709)
• Gollins, S. et al., 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017) - multidisciplinary management. Colorectal Disease 19 (S1), pp.37-66. (10.1111/codi.13705)
• Lal, N. et al., 2017. Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. The Journal of Pathology: Clinical Research 3 (3), pp.155-170. (10.1002/cjp2.70)
• Hendry, M. et al., 2017. Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open 7 (6) e015413. (10.1136/bmjopen-2016-015413)
• Renfro, L. A. et al., 2017. Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the Aide et Recherche en Cancérologie digestive database. Journal of Clinical Oncology 35 (17), pp.1929-1937. (10.1200/JCO.2016.71.5771)
• Glynne-Jones, R. et al., 2017. Clinical endpoints in trials of chemoradiation for patients with anal cancer. Lancet Oncology 18 (4), pp.e218-e227. (10.1016/S1470-2045(17)30190-0)
• Madi, A. et al., 2017. Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. Journal of Medical Genetics 54 (8), pp.567-571. (10.1136/jmedgenet-2016-104317)
• Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35 (7), pp.154-154. (10.1200/JCO.2017.35.7_suppl.154)
• Seligmann, J. et al., 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology 28 (3), pp.562-568. (10.1093/annonc/mdw645)
• Adams, R. 2017. Surveillance of anal canal cancers. Surgical Oncology Clinics of North America 26 (1), pp.127-132. (10.1016/j.soc.2016.07.007)
• Wood, G. et al., 2017. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status. Anti-Cancer Drugs 28 (5), pp.546-550. (10.1097/CAD.0000000000000488)

2016

• Franko, J. et al., 2016. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology 17 (12), pp.1709-1719. (10.1016/S1470-2045(16)30500-9)
• Muirhead, R. et al., 2016. Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology 29 (3), pp.188-197. (10.1016/j.clon.2016.10.005)
• Taylor, S. et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28 (10), pp.e139-e147. (10.1016/j.clon.2016.06.004)
• Gilbert, D. et al., 2016. Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: from consensus guidance to large-scale prospective audit, prior to future clinical trials. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO) Boston, MA, USA 25-28 September 2016. Vol. 96.Vol. 2. Elsevier. , pp.S105-S106. (10.1016/j.ijrobp.2016.06.260)
• Sebag-Montefiore, D. et al., 2016. The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO) Boston, MA, USA 25-28 September 2016. Vol. 96.Vol. 2. Elsevier. , pp.E164-E165. (10.1016/j.ijrobp.2016.06.1006)
• Weber, A. M. et al., 2016. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget 7 (38), pp.60807-60822. (10.18632/oncotarget.11845)
• Sharma, R. A. et al., 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13 , pp.627-642. (10.1038/nrclinonc.2016.79)
• Hendry, M. et al., 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6 (4) e011205. (10.1136/bmjopen-2016-011205)
• Ciardiello, F. et al., 2016. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The Oncologist 21 (3), pp.292-300. (10.1634/theoncologist.2015-0279)
• Morris, E. J. A. et al., 2016. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clinical Oncology 28 (8), pp.522-531. (10.1016/j.clon.2016.02.002)
• Grenader, T. et al., 2016. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. British Journal of Cancer 114 (6), pp.612-615. (10.1038/bjc.2016.23)
• Renfro, L. A. et al., 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34 (2), pp.144-150. (10.1200/JCO.2015.61.6441)
• Hubbard, G. et al., 2016. Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study. BMJ Open 6 (1) e009284. (10.1136/bmjopen-2015-009284)

2015

• Richman, S. D. et al., 2015. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology 69 (1), pp.35-41. (10.1136/jclinpath-2015-203097)
• Hutchinson, R. A. et al., 2015. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine 13 217. (10.1186/s12967-015-0531-z)
• Shi, Q. et al., 2015. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology 33 (1), pp.22-28. (10.1200/JCO.2014.56.5887)

2014

• Barbieri, M. et al., 2014. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Applied Health Economics and Health Policy 12 (5), pp.497-510. (10.1007/s40258-014-0115-8)
• Wasan, H. et al., 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. The Lancet Oncology 15 (6), pp.631-639. (10.1016/S1470-2045(14)70106-8)
• Glynne-Jones, R. et al., 2014. End points in anal cancer: Hopes for a common language. Journal of Clinical Oncology 32 (12), pp.1281-1282. (10.1200/JCO.2014.55.1515)
• Munro, J. et al., 2014. CRIB-the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4 (2) e004684. (10.1136/bmjopen-2013-004684)
• Adams, R. and Maughan, T. 2014. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Review of Anticancer Therapy 7 (4), pp.503-518. (10.1586/14737140.7.4.503)
• Baillie, J. et al. 2014. Developing meaningful public involvement in a cancer clinical trials unit. Presented at: COMET IV Meeting: Core Outcome Measures in Effectiveness Trials Rome, Italy 20-21 November 2014.
• Maughan, T. et al., 2014. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): A model for randomised controlled trials in the era of personalised medicine?. British Journal of Cancer 110 , pp.2178-2186. (10.1038/bjc.2014.182)
• Muirhead, R. et al., 2014. Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26 (11), pp.720-721. (10.1016/j.clon.2014.08.001)

2013

• Glynne-Jones, R. et al., 2013. Prognostic factors for recurrence and survival in anal cancer. Cancer 119 (4), pp.748-755. (10.1002/cncr.27825)
• Smith, C. et al. 2013. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clinical Cancer Research 19 (15), pp.4104-4113. (10.1158/1078-0432.CCR-12-2581)
• Smith, C. et al. 2013. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Human Mutation 34 (7), pp.1026-1034. (10.1002/humu.22333)
• Türbachova, I. et al., 2013. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics 8 (11), pp.1226-1235. (10.4161/epi.26334)

2012

• Madi, A. et al., 2012. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer 107 (7), pp.1037-1043. (10.1038/bjc.2012.384)
• Dunlop, M. G. et al., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk [Letter]. Nature Genetics 44 (7), pp.770-776. (10.1038/ng.2293)
• Gwynne, S. et al. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24 (1), pp.52-63. (10.1016/j.clon.2011.10.001)
• Gwynne, S. H. et al. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24 (4), pp.250-260. (10.1016/j.clon.2011.07.012)
• Vale, C. L. et al., 2012. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews 38 (6), pp.618-625. (10.1016/j.ctrv.2011.11.002)

2011

• Glynne-Jones, R. et al., 2011. "Mind the gap" - The impact of variations in the duration of the treatment gap and overall treatment time in the first UK anal cancer trial (ACT I). International Journal of Radiation Oncology*Biology*Physics 81 (5), pp.1488-1494. (10.1016/j.ijrobp.2010.07.1995)
• Adams, R. A. et al. 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology 12 (7), pp.642-653. (10.1016/S1470-2045(11)70102-4)
• Maughan, T. S. et al. 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 377 (9783), pp.2103-2114. (10.1016/S0140-6736(11)60613-2)
• Shaw, P. and Adams, R. A. 2011. Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy 11 (10), pp.1543-1553. (10.1586/era.11.143)

2010

• Maughan, T. et al. 2010. Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option [Letter]. Journal of Clinical Oncology 28 (17), pp.e275-e276. (10.1200/JCO.2009.27.8218)

2009

• Adams, R. , Maughan, T. and Crosby, T. 2009. Colon and rectum. In: Hanna, L. , Crosby, T. and Macbeth, F. eds. Practical Clinical Oncology. Cambridge University Press. , pp.159-173. (10.1017/CBO9780511545375.014)
• Adams, R. A. et al. 2009. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. British Journal of Cancer 100 (2), pp.251-258. (10.1038/sj.bjc.6604877)
• Clements, D. et al. 2009. Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Disease 11 (8), pp.845-848. (10.1111/j.1463-1318.2008.01695.x)
• Morgan, M. A. et al., 2009. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. British Journal of Surgery 96 (11), pp.1300-1307. (10.1002/bjs.6705)
• Wadhawan, A. , Stephens, R. and Adams, R. 2009. Intermittent therapy in the palliative treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 9 (1), pp.125-134. (10.1586/14737140.9.1.125)

2008

• Adams, R. et al. 2008. Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy 8 (8), pp.1237-1245. (10.1586/14737140.8.8.1237)

2007

• Adams, R. et al. 2007. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. EJSO - European Journal of Surgical Oncology 33 (3), pp.307-313. (10.1016/j.ejso.2006.10.026)
• Shaw, P. H. S. et al. 2007. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clinical Oncology 19 (1), pp.87-95. (10.1016/j.clon.2006.09.009)

1993

• Hardie, K. R. , Adams, R. A. and Towner, K. J. 1993. Transferrin-binding ability of invasive and commensal isolates of Haemophilus spp.. Journal of Medical Microbiology 39 (3), pp.218-224. (10.1099/00222615-39-3-218)